Synergy Pharmaceuticals Inc. – Agreement and Plan of Merger (July 23rd, 2012)
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of July 20, 2012, by and between SYNERGY PHARMACEUTICALS INC., a Delaware corporation (Synergy), and CALLISTO PHARMACEUTICALS, INC., a Delaware corporation (the Callisto).
Synergy Pharmaceuticals Inc. – Contract (August 2nd, 2011)
A Phase IIa Randomized, Double Blind, Placebo-Controlled, 14-Day Repeat, Oral, Range-Finding Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Plecanatide (SP-304) in Patients with Chronic Idiopathic Constipation Protocol No. SP304201-09) A Phase IIa Randomized, Double Blind, Placebo-Controlled, 14-Day Repeat, Oral, Range-Finding Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Plecanatide (SP-304) in Patients with Chronic Idiopathic Constipation (Protocol No. SP-SP304201-09) P762 K. Shailubhai, C. Talluto, S. Comiskey, J. Foss, A. Joslyn, and G. Jacob Synergy Pharmaceuticals, Inc., New York, NY and Doylestown, PA Uroguanylin (UG) and guanylin (GN) are physiological agonists of the guanylate cyclase-C (GC-C) receptor. Activation of the GC-C receptor stimulates intracellular synthesis of cyclic GMP, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR). Activation of CFTR results in augmented flow of
Penwest Pharmaceuticals Co. – Contract (May 10th, 2007)
Exhibit 10.4 SEVERANCE AND SETTLEMENT AGREEMENT AND RELEASE This AGREEMENT is entered into by and between Penwest Pharmaceuticals Co. (the "Company") and ALAN JOSLYN (the "Employee"). WHEREAS, the parties wish to resolve amicably the Employee's separation from the Company and establish the terms of the Employee's severance arrangement; NOW, THEREFORE, in consideration of the promises and conditions set forth herein, the sufficiency of which is hereby acknowledged, the Company and the Employee agree as follows: 1. Termination Date. The Employee's effective date of termination from the Company is FEBRUARY 9, 2007. 2. Monetary Consideration. In return for the execution of the instant Severance and Settlement Agreement and Release, the Company agrees to continue to pay the Employee's salary, for the period that the Employee remains unemployed, at the rate of $10,231 per pay period for up to six (6) months from the termination